Streetbeat News

BVNKF

Bavarian Nordic A/S

http://www.bavarian-nordic.com/

CEO

Paul Chaplin

Industry

Biological Product (except Diagnostic) Manufacturing

Open

23.37

Mkt cap

1.9B

Volume

108

High

24.23

P/E Ratio

13.17

52-wk high

46.05

Low

23.37

Div yield

N/A

52-wk low

18.72

Bavarian Nordic A/S held its Q4 2024 earnings call, discussing financial results and company performance. Key participants included the CEO, CFO, and Head of Investor Relations.

Portfolio Pulse from

March 05, 2025 | 7:15 pm

Bavarian Nordic's mpox vaccine sales have decreased following the outbreak, leading to reduced revenue and emphasizing the company's dependence on outbreak-driven demand. However, the Travel Health segment showed strength with a 21% YoY revenue increase, driven by rabies and tick-borne encephalitis vaccines. Bavarian Nordic is diversifying with the launch of a chikungunya vaccine, targeting a $500 million market by 2032.

Portfolio Pulse from

November 17, 2024 | 4:45 pm

Bavarian Nordic A/S held its Q3 2024 earnings call, discussing financial results for the nine months ending September 30, 2024. Key participants included Rolf Sass Sorensen, Paul Chaplin, and Henrik Juuel.

Portfolio Pulse from

November 15, 2024 | 4:00 pm

Bavarian Nordic's CEO anticipates increased U.S. biodefense funding despite concerns over vaccine skepticism due to Robert F. Kennedy Jr.'s nomination as health secretary.

Portfolio Pulse from

November 15, 2024 | 11:00 am

Bavarian Nordic has announced that it has secured orders worth $340 million for its mpox and smallpox vaccine, to be delivered in 2025. This includes previously announced deferred revenue.

Portfolio Pulse from

November 15, 2024 | 8:00 am

The UK government has secured over 150,000 doses of the mpox vaccine from Bavarian Nordic to combat the clade I mpox variant. The vaccines will be distributed by the NHS, prioritizing high-risk individuals. This move is part of a broader effort to address global health emergencies, with significant funding and collaboration with international organizations.

Portfolio Pulse from Vandana Singh

September 17, 2024 | 4:12 pm

Moderna's investigational mpox vaccine, mRNA-1769, shows greater effectiveness than the current Jynneos vaccine in animal studies. The vaccine is in Phase 1/2 trials, with results expected in 2025. BioNTech is also developing a similar vaccine. Moderna's stock is down 1.39%.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 6:02 pm

The Democratic Republic of Congo received its first batch of mpox vaccines, nearly two years after declaring an epidemic. The vaccines, MVA-BN, are produced by Bavarian Nordic A/S and are the only approved mpox vaccines in several regions. The delay in vaccine distribution is attributed to regulatory and logistical challenges.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 2:03 pm

Labcorp and Roche are increasing their mpox testing capabilities in response to a new virus strain. Labcorp can scale up from 500 to 25,000 tests monthly, while Roche is leveraging its HIV testing infrastructure. Quest Diagnostics and Abbott Laboratories are also involved in mpox testing.

Portfolio Pulse from Vandana Singh

August 26, 2024 | 5:36 pm

Bavarian Nordic has submitted clinical data to the European Medicines Agency to extend the use of its Imvanex vaccine to adolescents aged 12-17. The vaccine, known as Jynneos in the U.S., is currently approved for adults. The submission is based on a study showing similar immune responses and safety profiles in both adolescents and adults. Bavarian Nordic is also planning a trial for children aged 2-12. The company has a stock of ready-to-ship doses and expects to deliver 2 million doses by the end of the year. Bavarian Nordic's stock rose 15.39% to $14.02.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 2:44 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.